Literature DB >> 33640757

The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?

Fatemeh Sadoughi1, Liaosadat Mirsafaei2, Parisa Maleki Dana3, Jamal Hallajzadeh4, Zatollah Asemi5, Mohammad Ali Mansournia6, Majid Montazer7, Mohammad Hosseinpour8, Bahman Yousefi9.   

Abstract

Up to now, many improvements have been made in providing more therapeutic strategies for cancer patients. The lack of susceptibility to common therapies like chemo- and radio-therapy is one of the reasons why we need more methods in the field of cancer therapy. DNA damage response (DDR) is a set of mechanisms which identifies DNA lesions and triggers the repair process for restoring DNA after causing an arrest in the cell cycle. The ability of DDR in maintaining the genome stability and integrity can be favorable to cancerous cells which are exposed to radiation therapy or are treated with chemotherapeutic agents. When DDR mechanisms are error-free in cancer cells, they can escape the expected cellular death and display resistance to treatment. In this regard, targeting different components of DDR can help to increase the susceptibility of advanced tumors to chemo- and radio-therapy.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATM; ATR; Chemo-resistance; DDR; PARP1; Radio-resistance

Year:  2021        PMID: 33640757     DOI: 10.1016/j.dnarep.2021.103074

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  5 in total

Review 1.  Medulloblastoma and the DNA Damage Response.

Authors:  Leon F McSwain; Kiran K Parwani; Shubin W Shahab; Dolores Hambardzumyan; Tobey J MacDonald; Jennifer M Spangle; Anna Marie Kenney
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 2.  CRISPR/Cas9 gene editing: a new approach for overcoming drug resistance in cancer.

Authors:  Mostafa Vaghari-Tabari; Parisa Hassanpour; Fatemeh Sadeghsoltani; Faezeh Malakoti; Forough Alemi; Durdi Qujeq; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-06-17       Impact factor: 8.702

3.  CDCA2 promotes tumorigenesis and induces radioresistance in oesophageal squamous cell carcinoma cells.

Authors:  Bing Xu; Hui Chen; Zhipeng Xu; Xijuan Yao; Xinchen Sun; Hongyan Cheng
Journal:  Mol Med Rep       Date:  2021-05-26       Impact factor: 2.952

Review 4.  Nanomedicines for Overcoming Cancer Drug Resistance.

Authors:  Tingting Hu; Hanlin Gong; Jiayue Xu; Yuan Huang; Fengbo Wu; Zhiyao He
Journal:  Pharmaceutics       Date:  2022-08-01       Impact factor: 6.525

5.  ATX-101, a Peptide Targeting PCNA, Has Antitumor Efficacy Alone or in Combination with Radiotherapy in Murine Models of Human Glioblastoma.

Authors:  Giovanni Luca Gravina; Alessandro Colapietro; Andrea Mancini; Alessandra Rossetti; Stefano Martellucci; Luca Ventura; Martina Di Franco; Francesco Marampon; Vincenzo Mattei; Leda Assunta Biordi; Marit Otterlei; Claudio Festuccia
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.